Literature DB >> 9302258

Cloning of a novel transcription factor-like gene amplified in human glioma including astrocytoma grade I.

U Fischer1, D Heckel, A Michel, M Janka, T Hulsebos, E Meese.   

Abstract

Gene amplification, which is generally considered to occur late in tumor development, is a common feature of high grade glioma. Up until now, there have been no reports on amplification in astrocytoma grade I. In this study, we report cloning and sequencing of a cDNA termed glioma-amplified sequence (GAS41) which was identified recently in a glioblastoma cell line by microdissection-mediated cDNA capture. This technique is tailored to isolate amplified genes from human tumors. An increased copy number of GAS41 was found in glioblastoma multiforme and astrocytoma III, and at a high frequency in astrocytoma grades I and II. Sequence comparison indicates a high homology between the GAS41 protein, the yeast and human AF-9 and the human ENL proteins. Both AF-9 and ENL belong to a new class of transcription factors, indicating that GAS41 might also represent a transcription factor. With GAS41 being the first gene found with increased copy number in low grade glioma, this study provides the first evidence that gene amplification can occur in early tumor development.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9302258     DOI: 10.1093/hmg/6.11.1817

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  33 in total

1.  The chicken lysozyme chromatin domain contains a second, widely expressed gene.

Authors:  Suyinn Chong; Arthur D Riggs; Constanze Bonifer
Journal:  Nucleic Acids Res       Date:  2002-01-15       Impact factor: 16.971

Review 2.  Reading chromatin: insights from yeast into YEATS domain structure and function.

Authors:  Julia M Schulze; Alice Y Wang; Michael S Kobor
Journal:  Epigenetics       Date:  2010-10-01       Impact factor: 4.528

3.  GAS41 is required for repression of the p53 tumor suppressor pathway during normal cellular proliferation.

Authors:  Jeong Hyeon Park; Robert G Roeder
Journal:  Mol Cell Biol       Date:  2006-06       Impact factor: 4.272

4.  GAS41 amplification results in overexpression of a new spindle pole protein.

Authors:  Jana Schmitt; Ulrike Fischer; Sabrina Heisel; Hilmar Strickfaden; Christina Backes; Alessia Ruggieri; Andreas Keller; Paul Chang; Eckart Meese
Journal:  Genes Chromosomes Cancer       Date:  2012-05-23       Impact factor: 5.006

5.  YEATS4 is a novel oncogene amplified in non-small cell lung cancer that regulates the p53 pathway.

Authors:  Larissa A Pikor; William W Lockwood; Kelsie L Thu; Emily A Vucic; Raj Chari; Adi F Gazdar; Stephen Lam; Wan L Lam
Journal:  Cancer Res       Date:  2013-10-29       Impact factor: 12.701

6.  The GAS41-PP2Cbeta complex dephosphorylates p53 at serine 366 and regulates its stability.

Authors:  Jeong Hyeon Park; Rebecca J Smith; Sheau-Yann Shieh; Robert G Roeder
Journal:  J Biol Chem       Date:  2011-02-11       Impact factor: 5.157

7.  Knockdown of YEATS4 inhibits colorectal cancer cell proliferation and induces apoptosis.

Authors:  Kun Tao; Jing Yang; Yuemei Hu; Anmei Deng
Journal:  Am J Transl Res       Date:  2015-03-15       Impact factor: 4.060

8.  Asf1-like structure of the conserved Yaf9 YEATS domain and role in H2A.Z deposition and acetylation.

Authors:  Alice Y Wang; Julia M Schulze; Emmanuel Skordalakes; Jennifer W Gin; James M Berger; Jasper Rine; Michael S Kobor
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-04       Impact factor: 11.205

9.  The YEATS domain of Taf14 in Saccharomyces cerevisiae has a negative impact on cell growth.

Authors:  Julia M Schulze; Caroline M Kane; Ana Ruiz-Manzano
Journal:  Mol Genet Genomics       Date:  2010-02-24       Impact factor: 3.291

10.  The YEATS family member GAS41 interacts with the general transcription factor TFIIF.

Authors:  Sabrina Heisel; Nunja C Habel; Nicole Schuetz; Alessia Ruggieri; Eckart Meese
Journal:  BMC Mol Biol       Date:  2010-07-12       Impact factor: 2.946

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.